Poxel announces preclinical outcomes on PXL770 for NASH Combinations
Category: #health  By Pankaj Singh  Date: 2020-05-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Poxel announces preclinical outcomes on PXL770 for NASH Combinations

Poxel SA, the France-based dynamic biopharmaceutical firm developing advanced drugs for metabolic diseases, has reportedly announced the preclinical outcomes for PXL770, the main molecule in its AMPK (adenosine monophosphate-activated protein kinase) platform.

Reportedly, the molecule was assessed in a rodent non-alcoholic steatohepatitis (NASH) model together with other main agents in development, including obeticholic acid (FXR agonist), semaglutide (GLP-1 receptor agonist), and MGL-3196 (thyroid receptor β agonist).

According to sources familiar with the knowledge of the matter, outcomes showed the potential of PXL770 as new NASH therapy that may produce additional benefits when combined with other agents with different mechanisms of action.

Apparently, PXL770 was also assessed in rodent models of DKD (Diabetic Kidney Disease) which also evaluated cardiac dysfunction and ALD (adrenoleukodystrophy / AMN (adrenomyeloneuropathy), a fatal disease characterized by neurodegeneration. These results showed that AMPK activation possibly leads to broader usefulness for other diseases mediated by metabolic pathway dysfunction.

Sources cite that the company conducted these clinical trials to further investigate applications of PXL770 in numerous metabolic diseases. Moreover, all  these clinical trials are in support of Phase 2 clinical study and NASH development program.

Speaking on which, David E. Moller, MD, CSO at Poxel said that AMPK is a convincing pharmaceutical target that has been detected to modulate both inflammatory and metabolic pathways and has the potential to treat numerous rare metabolic and chronic diseases.

Mr. Moller added that new preclinical data indicate the potential of PXL770 to show even better additive or synergistic benefits to treat the main causes of NASH in combination with other agents in development. The company is rather delighted at these new findings indicating the potential of PXL770 and AMPK activation for treating other chronic disorders ranging from most common to uncommon monogenic metabolic disorders, Mr. Moller said.
 

Source Credit - https://www.poxelpharma.com/en_us/news-media/press-releases/detail/152/poxel-announces-program-update-and-preclinical-results-on



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Dada Group partners with Ferrero for new snack food retail model
Dada Group partners with Ferrero for new snack food retail model
By Pankaj Singh

The new retail model will help Ferrero improve brand reach to younger online customers in China

Chinese on-demand delivery and retail platform, Dada Group has inked...

Aphena Pharma to complete expansion of Solid Dose Division by April
Aphena Pharma to complete expansion of Solid Dose Division by April
By Pankaj Singh

Aphena Pharma Solutions, a pharmaceutical services provider, has reportedly announced the continuous expansion of its Tennessee-based Solid Dose Division worth $21 million. This division is expected to be completed by ...

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...